Capricor Therapeutics to Hold Third Quarter 2014 Business Update Conference Call on November 12, 2014 at 4:30 p.m. ET
31 oct. 2014 08h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Oct. 31, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics Announces Acquisition of Intellectual Property Rights to Family of Natriuretic Peptides From Medtronic, Inc.
14 oct. 2014 08h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Oct. 14, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation
09 oct. 2014 08h22 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Oct. 9, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Announces Plans to Pursue Clinical Program for the Treatment of Duchenne Muscular Dystrophy With Cardiosphere-Derived Cells (CDCs)
06 oct. 2014 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Oct. 6, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc.(OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Presents Safety and Preliminary Efficacy Results From ALLSTAR Phase I Clinical Trial at TCT 2014
18 sept. 2014 08h26 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Sept. 18, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics Reports Second Quarter 2014 Financial & Business Highlights
13 août 2014 10h18 HE
|
Capricor Therapeutics, Inc.
Reports Encouraging Results From Phase I of the ALLSTAR Clinical Trial and Signed Exclusive License With Cedars-Sinai Medical Center for Exosomes IP Portfolio
Conference Call Scheduled for...
Capricor Therapeutics to Hold Second Quarter 2014 Business Update Conference Call on August 13, 2014 at 4:30 p.m. Eastern Time
04 août 2014 08h27 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Aug. 4, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics to prevent and treat heart disease, today...
Capricor Announces Encouraging Results From Phase I ALLSTAR Trial; Phase II Trial Underway
16 juil. 2014 07h59 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, July 16, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics to Present at the First Regenerative Medicine Forum at BIO International Convention
23 juin 2014 09h02 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, June 23, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics Speaks at Panel on Regulation of Stem Cell-Derived Therapeutic Products at DIA 2014 50th Annual Meeting
19 juin 2014 13h28 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, June 19, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...